Pascal Touchon net worth and biography

Pascal Touchon Biography and Net Worth

With more than 30 years of global biopharmaceutical leadership experience, Pascal Touchon joined Atara Biotherapeutics as President, Chief Executive Officer and member of the Board of Directors in June 2019. Pascal has committed his career to transforming the lives of patients with serious medical conditions through pioneering science, teamwork, and a commitment to excellence.

Previously Global Head, Cell & Gene and member of the Oncology Executive Committee at Novartis Oncology, he oversaw the Oncology Cell & Gene unit and had responsibility for the unit’s financial performance and its activities, including the global launch of KYMRIAH® (tisagenlecleucel), securing regulatory approval and reimbursement in major markets, expanding global CAR T manufacturing and technical operations, overseeing multiple new clinical studies, and building a strong leadership team.

Prior to that, he served as Global Head, Strategy, Business Development, Oncology at Novartis, where he was responsible for early commercial strategy, portfolio management, therapeutic integrity and established medicines, disruptive technologies, diagnostics, business development and external collaborations, and served as a member of the Oncology Executive Committee. Pascal has also held key leadership roles in research, marketing, general management, and business development at companies including Servier, Glaxo-Wellcome and Glaxo, Sanofi. He has also been a board member of Genoptix and Navigate Biopharma Services (Novartis companies) and Cogen Therapeutics (a Flagship Pioneering company).

Pascal holds a doctorate in veterinary medicine from Paul Sabatier University (Toulouse, France), a Diplôme d’Etudes Superieures Specialisees (DESS) in management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).

Beyond his passion for science and business, Pascal enjoys traveling with his family around the world, wine tasting with friends, watching rugby, and reading.

What is Pascal Touchon's net worth?

The estimated net worth of Pascal Touchon is at least $1.74 million as of August 16th, 2022. Dr. Touchon owns 457,287 shares of Atara Biotherapeutics stock worth more than $1,737,691 as of October 3rd. This net worth evaluation does not reflect any other investments that Dr. Touchon may own. Additionally, Dr. Touchon receives an annual salary of $1,110,000.00 as CEO at Atara Biotherapeutics. Learn More about Pascal Touchon's net worth.

How old is Pascal Touchon?

Dr. Touchon is currently 59 years old. There are 5 older executives and no younger executives at Atara Biotherapeutics. Learn More on Pascal Touchon's age.

What is Pascal Touchon's salary?

As the CEO of Atara Biotherapeutics, Inc., Dr. Touchon earned a total compensation package of $5,285,827.00 in 2020. Dr. Touchon earned a salary of $654,857.00, a bonus of $422,500.00, stock awards of $2,235,600.00, options awards of $1,959,208.00, and other compensation of $13,662.00. Learn More on Pascal Touchon's salary.

How do I contact Pascal Touchon?

The corporate mailing address for Dr. Touchon and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (650) 278-8930 and via email at [email protected] Learn More on Pascal Touchon's contact information.

Has Pascal Touchon been buying or selling shares of Atara Biotherapeutics?

Pascal Touchon has not been actively trading shares of Atara Biotherapeutics during the last ninety days. Most recently, Pascal Touchon sold 14,806 shares of the business's stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $5.04, for a transaction totalling $74,622.24. Following the completion of the sale, the chief executive officer now directly owns 457,287 shares of the company's stock, valued at $2,304,726.48. Learn More on Pascal Touchon's trading history.

Who are Atara Biotherapeutics' active insiders?

Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.

Are insiders buying or selling shares of Atara Biotherapeutics?

During the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 118,341 shares worth more than $1,249,345.34. The most recent insider tranaction occured on August, 16th when CEO Pascal Touchon sold 14,806 shares worth more than $74,622.24. Insiders at Atara Biotherapeutics own 4.0 % of the company. Learn More about insider trades at Atara Biotherapeutics.

Information on this page was last updated on 8/16/2022.

Pascal Touchon Insider Trading History at Atara Biotherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2022Sell14,806$5.04$74,622.24457,287View SEC Filing Icon  
6/27/2022Sell14,220$7.20$102,384.00472,093View SEC Filing Icon  
5/17/2022Sell13,913$5.32$74,017.16486,313View SEC Filing Icon  
11/16/2021Sell8,402$17.12$143,842.24View SEC Filing Icon  
8/17/2021Sell8,223$12.53$103,034.19336,891View SEC Filing Icon  
8/18/2020Sell4,807$12.09$58,116.63260,037View SEC Filing Icon  
6/25/2020Sell12,135$12.92$156,784.20264,844View SEC Filing Icon  
See Full Table

Pascal Touchon Buying and Selling Activity at Atara Biotherapeutics

This chart shows Pascal Touchon's buying and selling at Atara Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Atara Biotherapeutics Company Overview

Atara Biotherapeutics logo
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.88
Low: $3.65
High: $3.96

50 Day Range

MA: $4.06
Low: $2.85
High: $5.84

2 Week Range

Now: $3.88
Low: $2.83
High: $20.04


75,439 shs

Average Volume

1,619,618 shs

Market Capitalization

$366.12 million

P/E Ratio


Dividend Yield